Myocardial Infarction Trends and Forecast
The future of the global myocardial infarction market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global myocardial infarction market is expected to reach an estimated $3.5 billion by 2030 with a CAGR of 6.6% from 2024 to 2030. The major drivers for this market are rise in the prevalence of obesity, diabetes, and hypertension as well as cardiovascular disorders, technological developments and the growing adoption of novel therapeutic approaches, and increasing research and development activities in the healthcare industry.Myocardial Infarction by Segment
The study includes a forecast for the global myocardial infarction by route of administration, drug class, distribution channel, and region.Myocardial Infarction Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:
- Oral
- Injectable
Myocardial Infarction Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-Adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin-receptor Blockers
- Analgesics
Myocardial Infarction Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Myocardial Infarction Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Myocardial Infarction Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies myocardial infarction companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the myocardial infarction companies profiled in this report include:- Apotex
- AstraZeneca
- Bayer
- Boehringer-Ingelheim
- Daiichi Sankyo
- Bristol-Myers Squibb Company
- Mylan N.V.
- Novartis
- Par Pharmaceutical Companies
- Pfizer
Myocardial Infarction Market Insights
The report forecasts that oral will remain the larger segment over the forecast period because the medication for myocardial infarction can be injected intravenously or taken orally, as well as, rising adoption of minimally invasive treatment.Within this market, hospital pharmacies will remain the largest segment due to rising cases of cardiovascular diseases, as well as, increasing investment in hospital infrastructure and the use of contemporary technology.
North America will remain the largest region over the forecast period due to increase in the incidence and prevalence of cardiac disease, as well as the proportion of the population that is obese.
Features of the Global Myocardial Infarction Market
- Market Size Estimates: Myocardial infarction market size estimation in terms of value ($B).- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
- Segmentation Analysis: Myocardial infarction market size by route of administration, drug class, distribution channel, and region in terms of value ($B).
- Regional Analysis: Myocardial infarction market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different route of administration, drug class, distribution channel, and regions for the myocardial infarction market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the myocardial infarction market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the myocardial infarction market size?Answer: The global myocardial infarction market is expected to reach an estimated $3.5 billion by 2030.
Q2. What is the growth forecast for myocardial infarction market?
Answer: The global myocardial infarction market is expected to grow with a CAGR of 6.6% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the myocardial infarction market?
Answer: The major drivers for this market are rise in the prevalence of obesity, diabetes, and hypertension as well as cardiovascular disorders, technological developments and the growing adoption of novel therapeutic approaches, and increasing research and development activities in the healthcare industry.
Q4. What are the major segments for myocardial infarction market?
Answer: The future of the global myocardial infarction market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.
Q5. Who are the key myocardial infarction market companies?
Answer: Some of the key myocardial infarction companies are as follows:
- Apotex
- AstraZeneca
- Bayer
- Boehringer-Ingelheim
- Daiichi Sankyo
- Bristol-Myers Squibb Company
- Mylan N.V.
- Novartis
- Par Pharmaceutical Companies
- Pfizer
Answer: The report forecasts that oral will remain the larger segment over the forecast period because the medication for myocardial infarction can be injected intravenously or taken orally, as well as, rising adoption of minimally invasive treatment.
Q7. In myocardial infarction market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to increase in the incidence and prevalence of cardiac disease, as well as the proportion of the population that is obese.
Q.8 Do we receive customization in this report?
Answer: Yes, the publisherl provides 10% customization without any additional cost.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the myocardial infarction market by route of administration (oral and injectable), drug class (antiplatelet agents, glycoprotein IIb/IIIa inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, and analgesics), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Global Myocardial Infarction Market : Market Dynamics
3. Market Trends and Forecast Analysis from 2018 to 2030
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
5. Competitor Analysis
6. Growth Opportunities and Strategic Analysis
7. Company Profiles of Leading Players
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Apotex
- AstraZeneca
- Bayer
- Boehringer-Ingelheim
- Daiichi Sankyo
- Bristol-Myers Squibb Company
- Mylan N.V.
- Novartis
- Par Pharmaceutical Companies
- Pfizer
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.
LOADING...
